Drug intelligence / Profile preview

anti-R110 monoclonal antibody

Development stage: Preclinical
Lead developer: SinABiomedics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

The anti-R110 monoclonal antibody is a specialized diagnostic and therapeutic candidate developed by SinABiomedics. It specifically targets the IGLV3-21R110 (R110) biomarker, a unique B-cell light-chain rearrangement found in a subset of patients with high-risk Chronic Lymphocytic Leukemia (CLL). Currently, the antibody is employed as a diagnostic reagent for the identification of R110-positive CLL cells via flow cytometry. SinABiomedics is also advancing a therapeutic concept that leverages this antibody's specificity to selectively target and eliminate malignant CLL cells, potentially offering a precision medicine approach for patients harboring this specific biomarker.

Other names: anti-IGLV3-21R110 antibodyanti-IGLV-3-21R110 antibodyanti-IGLV 3-21R110 antibodyR110 antibodyR-110 antibodyR 110 antibody

Targets

IGLV3-21R110 (Immunoglobulin lambda variable 3-21 R110 neoepitope)

Beyond the preview

Go deeper on anti-R110 monoclonal antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-R110 monoclonal antibody.